About the Company:
EP Global Communications, Inc. is an Advanced Technology Research and Development company for both Medical Devices and Consumer Electronics Devices specializing in Microelectronic Mechanical Systems (MEMS). For more information about the company, please click on the banner above to be directed to the comapny website.
People, Products & Process:
EPGL has assembled an impressive team to propel the company into a bright future and to build shareholder value. Under the leadership of Michael Hayes EPGL underwent debt restructuring, assembly of a new management team, as well as medical and scientific personnel. Mr. Hayes has made it a singular priority to bring aboard only the world’s top professionals in the field of medical sciences to EPGL and thereby build the Company into a major player in the Medical Device Industry over the next several years. He has also committed to prioritizing shareholders and creating significant value for their investment over time. We have seen great evidence of the har work over the last couple years as EPGL has signed Development Agreements with CooperVision, Intel, and AT&T. EPGL is in negotiations to licence technology to CooperVision presently. On April 28th 2015, EPGL disclosed to shareholders that EPGL and AT&T have created joint Intellectual Properties and are now in the process of procuring those properties. Shareholders can expect developments on this in the near future.
One key team member that was brought on board is David Markus (Vice President, BioMEMS) Developer, As you will see David Markus is a Well Accomplished Engineer.
David T. Markus holds a Ph.D. in Biomedical Engineering and a MS in Electrical Engineering with an emphasis in MEMS Microelectronics and Biomedical. Dr. Markus spent 11 years with Raytheon and holds 8 US patents and has 9 other US Patents Pending. He has been involved in research for several of the world's leading technological institutions, including the Office of Naval Research in Arlington, Virginia, NASA Jet Propulsion Laboratory in Pasadena, CA and he has been published 15 times for various technical conferences. He was a principal investigator on SBIR DARPA Phase I and Phase II, and "Ultraflexible Substrate" for Macroelectronics Program by Dr. Robert Reuss at DARPA. He has been involved in the engineering and the development on seven surgical devices, including devices for Cataract surgery, Intra-Ocular Lens Delivery, Arthroscopy, Endodontic Endoscope, Micro Endoscope and Neural Electrodes. Additionally he was instrumental on developing three medical laboratory devices, including for In-Vitro Fertilization, PCR instrumentation and drug discovery.
The Company has significant know-how and Intellectual Property in the arena of BioMEMS and has invented new device technologies which include, but are not limited to the following:
|1. Advanced Power Source for Contact Lenses ||11. Advanced TopSpin Platform Technology for Development of Smart Medical Devices |
|2. Advanced Cell Regeneration Technology to Treat Eye Disease ||12. Advanced Device for Steam Cell Treatment Delivery |
|3. Advanced Cell Regeneration Technology to Treat Hearing Loss ||13. Advanced Device for Treatment of Prostate Tumors |
|4. Advanced Nerve Ablation Device ||14. Advanced Endoscopic Device |
|5. Advanced Epidural Device ||15. Advanced Device for Delievery of Micron Sized Drug Payloads |
|6. New & Promsing Treatment of Restinitis Pigmentosa ||16. New & Promising Device for Treatment of Macular Degeneration |
|7. Advanced Ablation Device for Nerve Treatment of Facial Glabballar Frownig ||17. New Advanced Contact Lens Device |
|8. New Advanced PowerSource for TopSpin Medical Devices ||18. Advanced Device For Delivery of Micro Mechanical Devices Into Body |
|9. Advanced Trigger Point Needle Device ||19. Device for Advanced Biopsy |
|10. Advanced Micron Resolution Motor for Smart Medical Devices ||20. Real-Time Sensor Technologies for Connectivity to a Global Network **NEW |
21.Real-Time Data Applications for Athletic Teams, Workforces and Military Forces*NEW
EPGL develops advanced technololgies and in negotiations currently to license them to medical device companies and consumer electronic companies.
Contract with CooperVision:
EPGL and CooperVision, Inc. (CooperVision) have signed an exclusive Development Agreement for Advanced Ophthalmic and Medical Technologies. CooperVision is a market leader in the manufacturing and marketing of contact lenses. The Cooper Companies recently completed the acquisition of Sauflon Pharmaceuticals Limited for approximately $1.2 Billion Dollars.
Material Disclosure to Shareholdrs EPGL MED JOINT PATENT VALIDATION
(Includes EPGL MED, COOPERVISION, David T.Markus, Aurthur Back, Luke A.Kilyk, Michael Hayes)
CooperVision, Inc. Seeks Intermediary as EP Global Communications, Inc., Opens Negotiations at $1.1B Ophthalmic Technologies Discoveries Could Revolutionize the Future of Eye Care
CooperVision, Inc. Asks EP Global Communications, Inc. to Grant Option to License Immediately EPGL Considering its Options in Light of the Early Request
Exclusive Development Agreement Signed with CooperVision, Inc., a Division of The Cooper Companies, Inc. (COO, NYSE)
Contract with Intel:
On September 24, 2014, EP Global Communications, Inc. (EPGL) and Intel Corporation (Intel) executed an Initial Agreement. Additional Agreements are now pending. EPGL management believes that a relationship with Intel will be advantageous to shareholders as the two companies have synergistic goals in various fields. Details of further Agreements will be available upon mutual decision of the parties to disclose them publicly.
On September 24, 2014, EP Global Communications, Inc. (EPGL) and Intel Corporation (Intel) executed an initial Agreement. Additional Agreements are now pending.
Contract with AT&T:
A new Development Agreement has been executed between AT&T and EPGL on January 4, 2015. As a result of this agreeement Joint Intellectual Properties are now being developed certain data streaming projects in mind. EPGL continues to create new and innovative technologies with large companies
New** EPGL and AT&T have created joint Intellectual Properties and are now in the process of procuring those properties (4/28/15)
EPGL and AT&T Developing Joint Intellectual Properties Companies Sign Development Agreement Resulting in New Inventions in IoT Data Streaming Space
EPGL and AT&T Sign Development Agreement
About EPGL Medical Science's Share Structure :
EPGL has a share structure of 5 billion authorized shares with approximately 4.5 billion shares restricted and a float of approximately 499 million. Following a very successful Reverse Split EPGL has decreased the float by 90% and increased share holder value by over 500% since that time. The company has strongly stated many times that they will not sell shares into the retail market. They are here to build a real company and implement real growth. Since restructuring EPGL has not increased the Float/OS/AS and have given us there word on countless occasions they will not do so. As of Start of January 2015 Pricewaterhouse Coopers and EPGL Reach Agreement to Reduce Outstanding and Authorized Shares. Reduction of A/S and O/S is currently ongoing and first evidence of EPGL reducing shares will be shown in upcoming Quartley Report Q3, 2015
LINKS TO SHARE RETIREMENT
** Press Release ** - Pricewaterhouse Coopers and EPGL Reach Agreement to Reduce Outstanding and Authorized Shares Beginning January 2015
** OTC Disclosure ** - Supplemental Information- Retirement of Common Shares by Beneficial Shareholders Commences
Pricewaterhouse Coopers, Corporate Finance and Recovery (Cayman) Ltd.Controlling Agent for:
AJW Qualified Partners, LLC, Controlled by PwC (PricewaterhouseCoopers) Worlds Largest Accounting Firm
1.975 Billion Common Shares
Mr. Michael Hayes
1.975 Billion Common Shares
FLOAT/TRADABLE SHARES : 499 Million ***Unchanged since Restruture in 2012***
Total number of shareholders of record 700 approximate
The Company leases or utilizes facilities in the following locations
Various California Bay Area Research Facilities Under NDA, David T. Markus, Ph.D.
Irvine, California – Research Facilities, Office
New York University Langone Medical Center, Corey W. Hunter M.D. / Eric Lee M.D.
University of Minnesota, David T. Markus, Ph.D.
University of California at Irvine, David T. Markus, Ph.D.
Dallas and Plano Texas, David T. Markus, Ph.D. **NEW**
Additional Information :
Letter From PricewaterhouseCoopers (Ian Stokoe) Congratulating EPGL on First Devlopment Agreement (CooperVision)
Follow EPGL on Twiter @epglMED https://twitter.com/EPGLMed
Follow EPGL on the WEB at http://www.epglmed.com